EspeRare is honoured to contribute to the scientific session of the Senate of the Swiss Academy of Medical Sciences (SAMS/ASSM) in Bern on 18 June 2026.
As part of the mini-symposium “New therapies and rare diseases ”, which will also feature contributions from EspeRare’s partners Dr Roxane van Heurck of Geneva University Hospitals and Prof. Vladimir Katanaev of the University of Geneva, Caroline Kant, Executive Director of EspeRare, will give a presentation entitled:
“From molecular diagnosis to precision-medicine pathways for children with severe rare genetic diseases”
The session will bring together complementary perspectives on emerging therapeutic opportunities for rare genetic diseases, including antisense oligonucleotides, clinical implementation, and the broader transition toward individualized precision-therapy pathways.
Her presentation will address how molecular diagnosis can become the starting point for a personalized treatment path and what clinical, regulatory and access infrastructure is needed to make this possible in Switzerland.
EspeRare will share lessons from its partnership with n-Lorem Foundation and Geneva University Hospitals (HUG) to help enable access to individualized antisense oligonucleotides therapies for Swiss patients. The presentation will also highlight EspeRare’s collaboration with Prof. Vladimir Katanaev at the University of Geneva and Life House to explore personalized drug repositioning approaches for children with severe genetic neurodevelopmental diseases.
Together, these initiatives illustrate EspeRare’s commitment in helping translate molecular diagnosis into responsible precision-medicine pathways for children with rare genetic diseases.
Learn more about the Swiss Academy of Medical Sciences: https://www.samw.ch/en.html
